Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review
Biomolecules and Biomedicine · 03.01.2024 · 24 (1) · 14-29
DOI: 10.17305/bb.2023.9265 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules and Biomedicine, online erschienen am 03.01.2024. Verfasst von Marek Zdrenka und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anti-programmed cell death ligand 1 (anti-PD-L1) immunotherapy is an increasingly crucial in cancer treatment. To date, the Federal Drug Administration (FDA) has approved four PD-L1 immunohistochemistry (IHC) staining protocols, commercially available in the form of "kits", facilitating testing for PD-L1 expression. These kits comprise four PD-L1 antibodies on two separate IHC platforms, each utilizing distinct, non-interchangeable scoring systems. Several factors, including tumor heterogeneity and the size of the tissue specimens assessed, can lead to PD-L1 status misclassification, potentially hindering the initiation of therapy. Therefore, the development of more accurate predictive biomarkers to distinguish between responders and non-responders prior to anti-PD-1/PD-L1 therapy warrants further research. Achieving this goal necessitates refining sampling criteria, enhancing current methods of PD-L1 detection, and deepening our understanding of the impact of additional biomarkers. In this article, we review potential solutions to improve the predictive accuracy of PD-L1 assessment in order to more precisely anticipate patients' responses to anti-PD-1/PD-L1 therapy, monitor disease progression and predict clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland.
- Department of Cardiothoracic Surgery, Royal Papworth Hospital, Cambridge, UK.
- Medical University Pleven, Pleven, Bulgaria.
- Department of Pathomorphology, Jagiellonian University Medical College, Kraków, Poland.
- Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clinical Placentology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
- Department of Tumor Pathology and Pathomorphology, Oncology Centre-Prof. Franciszek Łukaszczyk Memorial Hospital, Bydgoszcz, Poland; Department of Obstetrics, Gynaecology and Oncology, Chair of Pathomorphology and Clini…
Zitieren
APA
Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2024). Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review. Biomolecules and Biomedicine, 24(1), 14-29. https://doi.org/10.17305/bb.2023.9265
Vancouver
Zdrenka M, Kowalewski A, Ahmadi N, Sadiqi RU, Chmura Ł, Borowczak J, et al. Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review. Biomolecules and Biomedicine. 2024;24(1):14-29. doi:10.17305/bb.2023.9265
BibTeX
@article{Zdrenka2024,
author = {Zdrenka, Marek and Kowalewski, Adam and Ahmadi, Navid and Sadiqi, Rizwan Ullah and Chmura, Łukasz and Borowczak, Jędrzej and Maniewski, Mateusz and Szylberg, Łukasz},
title = {Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review},
journal = {Biomolecules and Biomedicine},
year = {2024},
volume = {24},
number = {1},
pages = {14--29},
doi = {10.17305/bb.2023.9265}
}
EUVIMED